On February 22, 2024 Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, reported that it will present new preclinical data on KVA12123, the Company’s anti-VISTA antibody, in acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Blood Cancer Discovery Symposium, to be held on March 4-6 in Boston, Massachusetts (Press release, Kineta, FEB 22, 2024, View Source;utm_medium=rss&utm_campaign=kineta-to-present-new-preclinical-data-on-its-anti-vista-antibody-kva12123-in-acute-myeloid-leukemia-at-the-aacr-blood-cancer-discovery-symposium [SID1234640390]). Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting the poster.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Poster Title: VISTA a potential new Immuno-oncology therapeutic target to treat human Acute Myeloid Leukemia
Date and Time: Tuesday, March 5, 2024
Time: 6:45 P.M.- 8:45 P.M. Eastern Time
Location: Westin Copley Place P21

The abstract will be published as a freely available supplement in an AACR (Free AACR Whitepaper) journal on the first day of the symposium. The poster will also be made available on the Kineta website following the presentation at the conference.